Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Interleukin-2 (IL-2) is an established therapeutic agent used for cancer immunotherapy. Since treatment efficacy is mediated by CD8(+) and NK cell activity at the tumour site, considerable efforts have focused on generating variants that expand these subsets systemically, as exemplified by IL-2/anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Vazquez-Lombardi, Rodrigo, Loetsch, Claudia, Zinkl, Daniela, Jackson, Jennifer, Schofield, Peter, Deenick, Elissa K., King, Cecile, Phan, Tri Giang, Webster, Kylie E., Sprent, Jonathan, Christ, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437307/
https://www.ncbi.nlm.nih.gov/pubmed/28497796
http://dx.doi.org/10.1038/ncomms15373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437307/
https://www.ncbi.nlm.nih.gov/pubmed/28497796
http://dx.doi.org/10.1038/ncomms15373

Ejemplares similares